Miza III investor SciSparc acquires 63.3 million shares

An anonymous representative of SciSparc reports SCISPARC LTD. - EARLY WARNING REGARDING ACQUISITION OF COMMON SHARES OF NEUROTHERA LABS INC. Pursuant to the requirements of applicable securities laws, SciSparc Ltd., a corporation incorporated under the laws of the State of Israel and listed on Nasdaq under the trading symbol SPRC, has issued the following news release with regard to SciSparc acquiring 63.3 million common shares in the capital of Neurothera Labs Inc. (formerly Miza III Ventures Inc.), four million common share purchase warrants and 48 million contingent rights of the company on Oct. 22, 2025, pursuant to the completion of a reverse takeover involving the transfer to the company of all of the shares of SciSparc Nutraceuticals Inc. held by SciSparc (representing 50.86 per cent of the issued and outstanding shares of SNI) and certain assets of SciSparc. The payment warrants entitle SciSparc to acquire one common share of the company at a price of 25 cents per common share until Oct. 22, 2030. The qualifying transaction triggered the requirement to file an early warning report. Immediately prior to the qualifying transaction, SciSparc did not hold any common shares in the capital of the company. Immediately following the completion of the qualifying transaction, SciSparc acquired 63.3 million common shares, four million payment warrants and 48 million contingent rights, representing approximately 75 per cent on a non-diluted basis and 84.53 per cent of the issued and outstanding shares on a partially diluted basis. The deemed value of the acquired common shares is 25 cents per common share. The 48 million contingent rights are exercisable into up to an equal number of shares contingent upon meeting certain predetermined milestones. The holdings in securities of the company by SciSparc are for investment purposes. SciSparc does not currently have plans to acquire additional securities or dispose of its holdings in the company. However, it may acquire or dispose of securities depending on market conditions, changes in plans or other relevant factors, subject in each case to applicable securities law. A copy of the related early warning report may be obtained from the SEDAR+ website or from SciSparc at 972-3-610-3100 or by e-mail at [email protected].